Novartis Ag (NVS) EBIAT (2009 - 2025)
Novartis Ag recorded quarterly EBIAT of $4.0 billion in Q2 2025, down 32.19% quarter-over-quarter from $5.9 billion in Q4 2024, and up 23.97% year-over-year from $3.2 billion in Q2 2024.
Novartis Ag's EBIAT history runs 16 years deep, the most recent figure standing at $4.0 billion for Q2 2025.
- In Q2 2025, EBIAT rose 23.97% year-over-year to $4.0 billion; the TTM figure through Jun 2025 stood at $17.8 billion (up 66.6% YoY), while the FY2025 annual figure was $14.0 billion, up 16.99% from the prior year.
- EBIAT came in at $4.0 billion for Q2 2025 at Novartis Ag, down from $5.9 billion in the prior quarter.
- In the past five years, EBIAT ranged from a high of $6.0 billion in Q2 2021 to a low of $514.0 million in Q1 2021.
- A 5-year average of $3.1 billion and a median of $3.6 billion in 2022 frame the typical range for EBIAT.
- Across the five-year window, EBIAT soared 164.95% in 2021 and tumbled 54.47% in 2023, its largest moves.
- Novartis Ag's EBIAT stood at $5.0 billion in 2021, then slipped by 20.99% to $3.9 billion in 2022, then increased by 17.81% to $4.6 billion in 2023, then rose by 28.69% to $5.9 billion in 2024, then slumped by 32.19% to $4.0 billion in 2025.
- According to Business Quant data, EBIAT over the past three periods registered $4.0 billion, $5.9 billion, and $3.2 billion for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -4.24 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.02 Bn |
| Dec 31, 2024 | 5.93 Bn |
| Jun 30, 2024 | 3.25 Bn |
| Dec 31, 2023 | 4.61 Bn |
| Jun 30, 2023 | 2.32 Bn |
| Mar 31, 2023 | 519.00 Mn |
| Dec 31, 2022 | 3.91 Bn |
| Sep 30, 2022 | 583.00 Mn |
| Jun 30, 2022 | 5.09 Bn |
| Mar 31, 2022 | 595.00 Mn |
| Dec 31, 2021 | 4.95 Bn |
| Sep 30, 2021 | 642.00 Mn |
| Jun 30, 2021 | 5.99 Bn |
| Mar 31, 2021 | 514.00 Mn |
| Dec 31, 2020 | 4.04 Bn |
| Sep 30, 2020 | 604.00 Mn |
| Jun 30, 2020 | 5.60 Bn |
| Mar 31, 2020 | 194.00 Mn |
| Jun 30, 2019 | 2.11 Bn |
| Mar 31, 2019 | 499.00 Mn |
| Dec 31, 2018 | 485.00 Mn |
| Sep 30, 2018 | 587.00 Mn |
| Jun 30, 2018 | 7.73 Bn |
| Mar 31, 2018 | 627.00 Mn |
| Dec 31, 2017 | 513.00 Mn |
| Sep 30, 2017 | 587.00 Mn |
| Jun 30, 2017 | 1.98 Bn |
| Mar 31, 2017 | 523.00 Mn |
| Dec 31, 2016 | 936.00 Mn |
| Sep 30, 2016 | 528.00 Mn |
| Jun 30, 2016 | 560.00 Mn |
| Mar 31, 2016 | 185.00 Mn |
| Dec 31, 2015 | 374.00 Mn |
| Sep 30, 2015 | 154.00 Mn |
| Mar 31, 2015 | 519.00 |
| Dec 31, 2014 | 553.00 |
| Sep 30, 2014 | 563.00 |
| Mar 31, 2014 | 514.00 |
| Sep 30, 2012 | 538.00 |
| Jun 30, 2012 | 602.00 |
| Mar 31, 2012 | 527.00 |
| Dec 31, 2011 | 999.00 |
| Sep 30, 2011 | 539.00 |
| Jun 30, 2011 | 561.00 |
| Mar 31, 2011 | 713.00 |
| Dec 31, 2010 | 2.27 Bn |
| Sep 30, 2010 | 618.00 |
| Jun 30, 2010 | 2,771.00 Bn |
| Mar 31, 2010 | 2,948.00 |
| Dec 31, 2009 | 2.32 Bn |
| Sep 30, 2009 | 2,112.00 |
| Jun 30, 2009 | 2,394.00 Bn |
| Mar 31, 2009 | 1,975.00 |